

Datasheet: HCA386

Description:	HUMAN ANTI AFLIBERCEPT
Specificity:	AFLIBERCEPT
Other names:	Eylea, Zaltrap
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD34644ia
Isotype:	lgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	•			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

Human IgG1 antibody (kappa light chain) selected from the HuCAL phage display library and expressed in a human cell line. This antibody is supplied as a liquid.

Preparation	Purified IgG prepared by affinity chromatography on Protein A
Source	HKB-11
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml
Immunogen	Aflibercept

Specificity

Human Anti-Aflibercept Antibody, clone AbD34644ia is a recombinant antibody that specifically recognizes the fusion protein drug aflibercept as well as the vascular endothelial growth factor receptor 1 (VEGFR1). It does not recognize vascular endothelial growth factor receptor 2 (VEGFR2). The antibody binds to free aflibercept and can be used to measure free aflibercept or aflibercept biosimilars in patient samples.

Clone AbD34644ia is a fully human recombinant monoclonal antibody with IgG1 isotype that can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. It is recommended as the detection antibody paired with the Human anti-Aflibercept Antibody, clone AbD38778da (HCA390) as the capture reagent.

Aflibercept (Eylea, Zaltrap) is a recombinant fusion protein consisting of the extra-cellular domain of human VEGF receptors 1 and 2, fused to the Fc portion of human IgG1. It is used to treat the 'wet' form of age-related macular degeneration (AMD) and impaired vision due to macular oedema. It is also used in the treatment of metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin and irinotecan in patients previously treated with an oxaliplatin-containing chemotherapy. Aflibercept binds to circulating VEGF-A and VEGF-B to inhibit their ability to promote angiogenesis.

View a summary of all anti aflibercept antibodies

Affinity

The intrinsic affinity of the monovalent form of Human anti Aflibercept antibody, clone AbD34644ia is K_D = 11 nM as measured by real time, label free molecular interaction analysis on immobilized Aflibercept

ELISA

Human anti Aflibercept antibody, clone AbD34644ia can be used in an indirect ELISA or as detection antibody for Aflibercept in a bridging ELISA together with <u>HCA390</u> as the capture reagent.

Protocol: PK Bridging ELISA

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee

12 months from date of despatch

Acknowledgements

This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.

Eylea is a trademark of Regeneron/Sanofi.

Zaltrap is a trademark of Regeneron/Bayer Healthcare.

Health And Safety Information

Material Safety Datasheet documentation #10040 available at: https://www.bio-rad-antibodies.com/SDS/HCA386

	10040
Licensed Use	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u> .

Related Products

Recommended Useful Reagents

HUMAN ANTI AFLIBERCEPT (HCA387)
HUMAN ANTI AFLIBERCEPT (HCA388)
HUMAN ANTI AFLIBERCEPT (HCA389)
HUMAN ANTI AFLIBERCEPT (HCA390)
HISPEC ASSAY DILUENT (BUF049A)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Worldwide

Tel: +44 (0)1865 852 700

Europe Tel: +49 (0) 89 8090 95 21

Fax: +44 (0)1865 852 739

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_us@bio-rad.com

 $\textbf{Email: antibody_sales_uk@bio-rad.com} \\ \textbf{Email: antibody_sales_de@bio-rad.com} \\$

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M432879:240913'

Printed on 12 Dec 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint